-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CAL-02 in Community Acquired Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CAL-02 in Community Acquired Pneumonia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CAL-02 in Community Acquired Pneumonia Drug Details: CAL-02 (combioxin) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – E-602 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - E-602 in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.E-602 in Ovarian Cancer Drug Details:E-602 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – E-602 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - E-602 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.E-602 in Non-Small Cell Lung Cancer Drug Details:E-602 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – E-602 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - E-602 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.E-602 in Solid Tumor Drug Details:E-602 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – E-602 in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - E-602 in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.E-602 in Gastroesophageal (GE) Junction Carcinomas Drug Details:E-602 is under development...
-
Company Insights
Innovation and Patenting activity of Eagle Pharmaceuticals Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Eagle Pharmaceuticals Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Track & Monitor
Chemotherapy in Pharmaceuticals: Platinum-based cancer drug compositions
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Platinum-based cancer drug compositions segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered...
-
Company Profile
Eagle Pharmaceuticals Inc – Company Profile
Eagle Pharmaceuticals Inc (Eagle) is a specialty pharmaceutical company that offers proprietary pharmaceutical injectables in the therapy areas of critical care, oncology, and various orphan diseases. The company’s key commercial products encompass pharmaceutical injectables, including Ryanodex for exertional heatstroke; Bendeka, and Belrapzo, both for the treatment of chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin’s lymphoma (NHL). Pipeline products of the company include EP-4104 (dantrolene sodium) for exertional heat stroke (EHS) and nerve agent exposure; EA-114 (fulvestrant) for the treatment...
Add to Basket -
Product Insights
Net Present Value Model: Vasopressin
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Vasopressin Drug Details Vasopressin is a...